The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten

Insulet (NASDAQ: [[ticker:PODD]])
Cash on hand: $52.3 million
Related Xconomy coverage:
“The Greater Boston Diabetes Cluster”

Inverness Medical Innovations (NYSE: [[ticker:IMA]])
Cash on hand: $425.5 million
Related Xconomy coverage:
“Inverness to Raise $200M in Notes Sale”

Javelin Pharmaceuticals (AMEX: [[ticker:JAV]])
Cash on hand: $7.3 million
Related Xconomy coverage:
“Javelin Pharma Stock Takes Hit”

Millipore (NYSE: [[ticker:MIL]])
Cash on hand: $146.6 million
Related Xconomy coverage:
“Millipore Buys Guava”

Molecular Insight Pharmaceuticals (NASDAQ: [[ticker:MIPI]])
Cash on hand: $82.9 million
Related Xconomy coverage:
“Imaging Agent for Early Detection of Heart Disease From Molecular Insight Reaches Goal”

Momenta Pharmaceuticals (NASDAQ: [[ticker:MNTA]])
Cash on hand: $72.1 million
Related Xconomy coverage:
“Momenta Pharma Competitor Lodges Ethics Complaint Against FDA Boss, WSJ Reports”
“Momenta Gets Some Mojo as FDA Agrees to Review Application of Generic MS Drug”

NxStage Medical (NASDAQ: [[ticker:NXTM]])
Cash on hand: $24.5 million
Related Xconomy coverage:

Parexel International (NASDAQ: [[ticker:PRXL]])
Cash on hand: $96.3 million
Related Xconomy coverage:
“Parexel to Purchase Clinphone for $182M”

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button. For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. *Price is subject to change without notice

PerkinElmer (NYSE: [[ticker:PKI]])
Cash on hand: $151.3 million
Related Xconomy coverage:
“PerkinElmer Sacrifices Short Term Profits to Preserve R&D, Buy Technologies on the Cheap”

Repligen (NASDAQ: [[ticker:RGEN]])
Cash on hand: $62 million
Related Xconomy coverage:
“Repligen BMS Settle Patent Suit”

RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]])
Cash on hand: $4.4 million
Related Xconomy coverage:
“RXi Announces $8.3M Offering”
“Oral RNAi Drug Stops Inflammation in Mice, RXi Says”
“RXi Eyes a Future of RNAi Drugs You Take as Oral Pills”
“Alnylam, RXi on Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative”
“RXi Takes an Untraditional Route to the Public Market, Now Working to Get Pharma to Pay the Bills”

Sepracor (NASDAQ: [[ticker:SEPR]])
Cash on hand: $707.2 million
Related Xconomy coverage:
“Drugmaker Sepracor Accepts $2.6B Buyout Offer From Japan’s Dainippon”

Synta Pharmaceuticals (NASDAQ:SNTA)
Cash on hand: $60.5 million
Related Xconomy coverage:
“Glaxo Ends Synta Partnership”
“Synta Melanoma Drug Disastrously in Clinical Trial as Patients Show Higher Death Rate”
“Synta, Developer of New Class of Cancer Drugs, Eagerly Awaits Results From Key Trial”

Thermo Fisher Scientific (NYSE: [[ticker:TMO]])
Cash on hand: $1.43 billion
Related Xconomy coverage:
“Thermo Fisher Names New CEO”

Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]])
Cash on hand: $754.4 million
Related Xconomy coverage:
“Vertex Drug Could Be Man Walking on the Moon for Cystic Fibrosis, Says Seattle Researcher Bonnie Ramsey”
“Vertex Acquires Virochem for $375M to Make Cocktail Treatments for Hepatitis C”
“Vertex Fending Off Competitors By Treating the Toughest Patients With Hepatitis C”
“Vertex CEO Josh Boger Retiring in May, Matthew Emmens to Fill Role”
“Out With the Hedge Funds, In With Blue Bloods, Vertex Transforms Investor Base Via Stock Sale”

Waters (NYSE: [[ticker:WAT]])
Cash on hand: $505.7 million

Zoll Medical (NASDAQ: [[ticker:ZOLL]])
Cash on hand: $55.3 million
Related Xconomy coverage:
“Zoll Medical to Buy Alsius for $12m“